Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting
Open Access
- 19 January 1999
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (2) , 628-633
- https://doi.org/10.1073/pnas.96.2.628
Abstract
Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that inhibits both the classical and the alternative pathways of complement activation. DAF has been studied extensively in humans under two clinical settings: when absent from the erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) patients, who suffer from complement-mediated hemolytic anemia, and in transgenic pigs expressing human DAF, which have been developed to help overcome complement-mediated hyperacute rejection in xenotransplantation. Nevertheless, the exact role of DAF in regulating complement activation in vivo on the cell surface and the species specificity of this molecule remain to be fully characterized. To address these issues, we have used gene targeting to produce mice lacking GPI-anchored DAF. We found that erythrocytes from mice deficient in GPI-anchored DAF showed no increase in spontaneous complement activation in vivo but exhibited impaired regulation of zymosan-initiated bystander and antibody-triggered classical pathway complement activation in vitro, resulting in enhanced complement deposition. Despite a high level of C3 fixation, no homologous hemolysis occurred. It is noteworthy that GPI-linked DAF knockout erythrocytes, when tested with human and guinea pig sera, were more susceptible to heterologous complement lysis than were normal erythrocytes. These results suggest that DAF is capable of regulating homologous as well as heterologous complement activation via the alternative or the classical pathway. They also indicate that DAF deficiency alone is not sufficient to cause homologous hemolysis. In contrast, when the assembly of the membrane-attack complex is not properly regulated, as in the case of heterologous complement activation or in PNH patients, impaired erythrocyte DAF activity and enhanced C3 deposition could lead to increased hemolytic reaction.Keywords
This publication has 42 references indexed in Scilit:
- Fetal loss and impaired fetomaternal tolerance in mice deficient in CRRY, a murine regulator of C3 activationMolecular Immunology, 1998
- Differentiation-dependent changes in human trophoblast expression of decay-accelerating factor are modulated by 3?,5? cyclic adenosine monophosphateJournal of the Society for Gynecologic Investigation, 1997
- Abnormalities of PIG-A Transcripts in Granulocytes from Patients with Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 1994
- The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of functionImmunology Today, 1992
- Complement regulatory proteins at the feto‐maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55)European Journal of Immunology, 1992
- Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogeneCell, 1991
- Studies on the sensitivity to complement‐mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor)British Journal of Haematology, 1989
- Identification of human erythrocyte blood group antigens on decay- accelerating factor (DAF) and an erythrocyte phenotype negative for dafThe Journal of Experimental Medicine, 1988
- The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.The Journal of Experimental Medicine, 1987
- Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.The Journal of Experimental Medicine, 1984